Complete and selective estrogenic effects on lipids and cardiovascular disease

Current Atherosclerosis Reports

Volumn 2, Issue 1, 2000, Pages 72-75

  Lamon Fava, Stefania ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Coronary Heart Disease; Estrogen; Postmenopausal Woman; Raloxifene; Tamoxifen

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; LIPID;

ARTERIOSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ESTROGEN THERAPY; FEMALE; HUMAN; LIPID METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LIPID METABOLISM; LIPIDS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ESTROGEN;

EID: 0033750334     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-000-0097-x     Document Type: Article

References (30)

1. Kannel WB, Hjortland MC, McNamara PM: Menopause and the risk of cardiovascular disease: The Framingham Study. Ann Intern Med 1976, 85:447–452.
2. Colditz GA, Willett WC, Stampfer MJ, et al.: Menopause and the risk of coronary artery disease. N Engl J Med 1987, 316:1105–1110. DOI: 10.1056/NEJM198704303161801
3. Nabulsi AA, Folsom AR, White A, et al.: Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993, 328:1069–1075. DOI: 10.1056/NEJM199304153281501
4. Bush TL, Barrett-Connor E, Cowan LD, et al.: Cardiovascular mortality and non-contraceptive use of of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987, 75:1102–1109.
5. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA: Post-menopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988, 115:954–963. DOI: 10.1016/0002-8703(88)90063-4
6. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995, 273:199–208. DOI: 10.1001/jama.273.3.199
7. Seman LJ, deLuca C, Jenner JL, et al.: Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem 1999, 45:1039–1046.
8. Seman LJ, McNamara JR, Schaefer EJ. Lipoprotein(a), homocysteine, and remanatlike particles: emerging risk factors. Curr Opin Cardiol 1999, 14:186–191. DOI: 10.1097/00001573-199903000-00017
9. Soma MR, Osnago-Gadda I, Paoletti R, et al.: The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med 1993, 153:1462–1468. DOI: 10.1001/archinte.153.12.1462
10. Sacks FM, McPherson R, Walsh BW: Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med 1994, 154:1106–1110. DOI: 10.1001/archinte.154.10.1106
11. Masuoka H, Ishikura K, Kamei S, et al.: Predictive value of remnant-like particles cholesterol/high-density lipoprotein cholesterol ratio as a new indicator of coronary artery disease. Am Heart J 1998, 136:226–230. DOI: 10.1053/hj.1998.v136.89586
12. Weintraub M, Grosskopf I, Charach G, Eckstein N, Rubistein A: Hormone replacement therapy enhances postprandial lipid metabolism in postmenopausal women. Metabolism 1999, 48:1193–1196. DOI: 10.1016/S0026-0495(99)90137-3
13. Bush TL, Miller VT: Effects of pharmacologic agents used during menopause: impact on lipids and lipoproteins. In Menopause: Physiology and Pharmacology. Edited by Mishell DR, Jr. Chicago: Year Book Medical Publishers; 1987, 187–208.
14. Crook D, Cust MP, Gangar MB, et al.: Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992, 166:950–955.
15. Chait A, Brunzell JD: Chylomicronemia syndrome. Adv Intern Med 1991, 37:249–273.
16. Chang J, Powles TJ, Ashley SE, et al.: The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density, and coagulation factors in healthy postmenopausal women participating in a randomized, controlled tamoxifen prevention study. Ann Oncol 1996, 7:671–675.
17. Bagdade JD, Wolter J, Subbaiah PV, Ryan W: Effects of tamoxifen treatment on plasma lipids and lipoprotein composition. J Clin Endocrinol Metab 1990, 70:1132–1135. DOI: 10.1210/jcem-70-4-1132
18. Decensi A, Bonanni B, Guerrieri-Gonzaga, et al.: Biological activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 1998, 90:1461–1467. DOI: 10.1093/jnci/90.19.1461
19. Shewmon DA, Stock JL, Rosen CJ, et al.: Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994, 4:586–593.
20. Delmas PD, Bjarnasos NH, Mitlak BH, et al.: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997, 337:1641–1647. DOI: 10.1056/NEJM199712043372301
21. Walsh BW, Kuller LH, Wild RA, et al.: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998, 279:1445–1451. DOI: 10.1001/jama.279.18.1445
22. Mijatovic V, van der Mooren MJ, Kenemans P, et al.: Raloxifene lowers serum lipoprotein(a) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens. Menopause 1999, 6:134–137. DOI: 10.1097/00042192-199906020-00010
23. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991, 20:47–63. DOI: 10.1016/0091-7435(91)90006-P
24. Grady D, Rubin SM, Petitti DB, et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992, 117:1016–1037.
25. Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605–613. DOI: 10.1001/jama.280.7.605
26. Hemminki E, McPherson K: Impact of postmenopausal hormonal therapy on cardiovascular events and cancer: pooled data from clinical trials. Br Med J 1997, 315:149–153.
27. Sourander L, Rajala T, Raiha I, et al.: Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 1998, 352:1965–1969. DOI: 10.1016/S0140-6736(98)05066-1
28. Grodstein F, Stampfer MJ, Falkeborn M, et al.: Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology 1999, 5:476–480. DOI: 10.1097/00001648-199909000-00003
29. Teede HJ, Liang Y-L, Shiel LM, et al.: Hormone replacement therapy in postmenopausal women protects against smoking-induced changes in vascular structure and function. J Am Coll Cardiol 1999, 34:131–137. DOI: 10.1016/S0735-1097(99)00155-2
30. Grady D: Postmenopausal hormone therapy: good for smokers? J Am Coll Cardiol 1999, 34:138–139. DOI: 10.1016/S0735-1097(99)00163-1